Experience in using Aterixen® in clinical practice. Results of the "SUPRA" observation program
Background. The new medical product Aterixen (XC221GI) has appeared on the pharmaceutical market in 2022. It was revealed, at preclinical stage, that the main anti-inflammatory drug's effect was assured by its effect on production of anti-inflammatory cytokines IL-6, IL-8 and chemokines IP-10 (...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
ZAO "Consilium Medicum",
2023-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |